Locations
Toronto, ON, Canada · North York, Toronto, ON, Canada
industry
Biotechnology
Size
11-50 employees
Stage
Other
founded in
2021
An estimated 85% of the ~3 billion base pairs in the human genome is transcribed into RNA, but only ~1.5% of these code for proteins. While the chemical properties of protein binders are increasingly understood and interrogated, the field of RNA-targeted drugs is relatively new and the properties of small molecules that drive specific and selective targeting of RNA, and associated assays, are yet to be developed. At Serna Bio (previously Ladder Therapeutics), we are using an AI-enabled, data-first approach to write the rules that define RNA-small molecule interactions. Our discovery platform powers our first-in-class small molecule programs targeted at classically undruggable proteins and non-coding RNA targets, targeting both human and non-human biology.
Something looks off?